"Pill-in-Pocket" Anticoagulation for Stroke Prevention in Atrial Fibrillation.
Graham PeighRod S PassmanPublished in: Journal of cardiovascular electrophysiology (2023)
Uninterrupted anticoagulation for atrial fibrillation (AF), regardless of AF burden, is deeply rooted in practice since the early anticoagulation trials. However, uninterrupted anticoagulation is not without risks, and may not be beneficial for allcomers with a history of AF. Indeed, contemporary data that support a critical duration threshold of AF that benefits from anticoagulation, and a temporal association between stroke and multi-hour AF episodes, compel the study of a more targeted approach to AF anticoagulation. In this review, we discuss data that support further investigation of "pill-in-the-pocket" anticoagulation for AF, and introduce the pivotal REACT-AF Trial that will robustly evaluate this strategy. This article is protected by copyright. All rights reserved.
Keyphrases
- atrial fibrillation
- catheter ablation
- direct oral anticoagulants
- left atrial
- oral anticoagulants
- left atrial appendage
- heart failure
- percutaneous coronary intervention
- healthcare
- clinical trial
- electronic health record
- randomized controlled trial
- big data
- primary care
- risk factors
- risk assessment
- brain injury
- left ventricular
- drug delivery
- cancer therapy
- open label
- phase ii
- cerebral ischemia